Compare Cadila Healthcare with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs IPCA LABS - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE IPCA LABS CADILA HEALTHCARE/
IPCA LABS
 
P/E (TTM) x 28.9 25.3 114.1% View Chart
P/BV x 4.6 7.9 58.9% View Chart
Dividend Yield % 0.7 0.2 483.5%  

Financials

 CADILA HEALTHCARE   IPCA LABS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
IPCA LABS
Mar-19
CADILA HEALTHCARE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3521,042 33.8%   
Low Rs207590 35.0%   
Sales per share (Unadj.) Rs139.2298.6 46.6%  
Earnings per share (Unadj.) Rs11.835.0 33.6%  
Cash flow per share (Unadj.) Rs18.649.4 37.6%  
Dividends per share (Unadj.) Rs3.503.00 116.7%  
Dividend yield (eoy) %1.30.4 340.8%  
Book value per share (Unadj.) Rs101.4247.1 41.0%  
Shares outstanding (eoy) m1,023.74126.35 810.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.02.7 73.4%   
Avg P/E ratio x23.723.3 101.9%  
P/CF ratio (eoy) x15.016.5 91.2%  
Price / Book Value ratio x2.83.3 83.5%  
Dividend payout %29.88.6 347.1%   
Avg Mkt Cap Rs m286,033103,108 277.4%   
No. of employees `00013.413.4 99.7%   
Total wages/salary Rs m24,1457,874 306.6%   
Avg. sales/employee Rs Th10,632.72,807.0 378.8%   
Avg. wages/employee Rs Th1,801.2585.8 307.5%   
Avg. net profit/employee Rs Th898.5329.0 273.1%   
INCOME DATA
Net Sales Rs m142,53137,732 377.7%  
Other income Rs m1,139577 197.5%   
Total revenues Rs m143,67038,309 375.0%   
Gross profit Rs m24,1986,901 350.7%  
Depreciation Rs m6,9651,824 381.8%   
Interest Rs m3,418189 1,811.3%   
Profit before tax Rs m14,9545,465 273.7%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1981,042 306.8%   
Profit after tax Rs m12,0444,422 272.4%  
Gross profit margin %17.018.3 92.8%  
Effective tax rate %21.419.1 112.1%   
Net profit margin %8.511.7 72.1%  
BALANCE SHEET DATA
Current assets Rs m87,15423,778 366.5%   
Current liabilities Rs m82,69410,975 753.5%   
Net working cap to sales %3.133.9 9.2%  
Current ratio x1.12.2 48.6%  
Inventory Days Days71104 68.8%  
Debtors Days Days9466 142.3%  
Net fixed assets Rs m133,23620,368 654.2%   
Share capital Rs m1,024253 405.2%   
"Free" reserves Rs m102,73330,971 331.7%   
Net worth Rs m103,75731,224 332.3%   
Long term debt Rs m32,1461,409 2,282.3%   
Total assets Rs m236,86645,507 520.5%  
Interest coverage x5.430.0 17.9%   
Debt to equity ratio x0.30 686.8%  
Sales to assets ratio x0.60.8 72.6%   
Return on assets %6.510.1 64.4%  
Return on equity %11.614.2 82.0%  
Return on capital %13.717.3 79.3%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m52,75217,308 304.8%   
Fx outflow Rs m14,5046,266 231.5%   
Net fx Rs m38,24811,042 346.4%   
CASH FLOW
From Operations Rs m25,0544,923 508.9%  
From Investments Rs m-10,123-1,563 647.6%  
From Financial Activity Rs m-10,942-1,832 597.3%  
Net Cashflow Rs m3,9891,528 261.1%  

Share Holding

Indian Promoters % 74.8 45.9 163.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 11.4 72.8%  
FIIs % 5.9 25.3 23.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.4 63.2%  
Shareholders   44,069 36,892 119.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ORCHID PHARMA  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower Tracking Mixed Global Cues; Tata Motors & Sun Pharma Top Losers(09:30 am)

Asian share markets are trading on a mixed note today. All eyes are on the US Federal Reserve policy outcome due later today.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 27, 2021 12:14 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS